lnu.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse
Lundbeck A/S, Denmark;Lund University, Sweden.
Lundbeck A/S, Denmark;Protein Lab., Denmark.
H. Lundbeck A/S, Denmark.
H. Lundbeck A/S, Denmark.ORCID iD: 0000-0001-5316-7726
2005 (English)In: Neuropharmacology, ISSN 0028-3908, E-ISSN 1873-7064, Vol. 48, no 4, p. 517-524Article in journal (Refereed) Published
Abstract [en]

The risk of Parkinson's disease (PD) is associated with a lower intake of caffeine, a non-selective adenosine A2A antagonist. In agreement, genetic or pharmacological inactivation of adenosine A2A receptors in animal models of PD has demonstrated both symptomatic and neuroprotective effects. These findings and the lack of disease modifying therapies have led to intense research on adenosine A2A antagonists as a novel treatment for PD. In the present study the neuroprotective effect of the A2A receptor antagonist KW-6002 was investigated using different models of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in mice, which induced dopaminergic terminal and or dopaminergic cell loss and inflammation. Treatment with KW-6002 prevented the loss of dopaminergic striatal terminals and nigral cell bodies and inhibited the nigral microglia activation. Our results confirm previous findings that pharmacological inactivation of A2A receptors inhibits MPTP-induced dopaminergic damage at the level of striatum. In addition, we demonstrate for the first time that, after MPTP treatment in mice, an A 2A antagonist is neuroprotective, and has anti-inflammatory effects, at the level of the substantia nigra. Thus, our data further support the use of A2A receptor antagonists as a novel neuroprotective therapy for PD

Place, publisher, year, edition, pages
Elsevier, 2005. Vol. 48, no 4, p. 517-524
National Category
Neurosciences
Research subject
Natural Science, Biomedical Sciences
Identifiers
URN: urn:nbn:se:lnu:diva-120720DOI: 10.1016/j.neuropharm.2004.11.009ISI: 000228087300005PubMedID: 15755479Scopus ID: 2-s2.0-14544287564OAI: oai:DiVA.org:lnu-120720DiVA, id: diva2:1756807
Available from: 2023-05-15 Created: 2023-05-15 Last updated: 2023-05-15Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full textPubMedScopus

Authority records

Englund Johansson, Ulrica

Search in DiVA

By author/editor
Englund Johansson, Ulrica
In the same journal
Neuropharmacology
Neurosciences

Search outside of DiVA

GoogleGoogle Scholar

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 31 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf